文献速递母胎医学产科

胎儿巨头畸形的产前外显子组测序:一项大型前瞻性观察性队列研究

Prenatal Exome Sequencing for Fetal Macrocephaly: A Large Prospective Observational Cohort Study.
PubMed 文献 · Prenat Diagn · 2025-05-22

本研究纳入87例头围≥+2 SD且染色体微阵列阴性的巨头畸形胎儿,行三人组外显子组测序,39.1%(34/87)获得分子诊断。非孤立性病例检出率65.0%(26/40)显著高于孤立性病例17.0%(8/47),p<0.001。相关变异主要涉及mTOR、RASopathies和Sotos综合征等信号通路。

要点

  • 三人组外显子组测序在巨头畸形胎儿中分子诊断率为39.1%(34/87)。
  • 非孤立性巨头畸形检出率65.0%(26/40)显著高于孤立性17.0%(8/47),p<0.001。
  • 孕32周前诊断、头围Z评分≥+3 SD、小肢畸形及无大于胎龄儿者检出率更高。

核心结论

  • 外显子组测序较染色体微阵列显著提高巨头畸形胎儿单基因病的检出,无论孤立性或非孤立性病例。
  • 这些临床特征和表型对评估单基因病及产前咨询和评估巨头畸形胎儿至关重要。

研究设计与样本

  • 前瞻性观察性队列研究,纳入头围≥+2 SD且染色体微阵列结果阴性、具有三人组外显子组测序数据的胎儿87例。
  • 系统分析分子诊断,并按孕周、头围Z评分、伴发异常和生长参数进行外显子组测序诊断率的亚组分析。

主要发现

  • 87例巨头畸形胎儿中34例(39.1%)通过三人组外显子组测序获得分子诊断。
  • 变异主要影响mTOR、RASopathies和Sotos综合征等关键信号通路。
  • 非孤立性巨头畸形检出率65.0%(26/40)vs 孤立性17.0%(8/47),p<0.001。
  • 与遗传诊断相关的最常见异常包括小肢畸形(100.0%,14/14)、巨脑(100.0%,2/2)和脑室扩大(60.0%,6/10)。
  • 亚组分析显示孕32周前诊断、头围Z评分≥+3 SD、小肢畸形及无大于胎龄儿的胎儿诊断率更高。

临床怎么用

  • 原文结论指出外显子组测序较染色体微阵列显著提高巨头畸形胎儿单基因病的检出,无论孤立性或非孤立性病例。
  • 原文结论指出这些临床特征和表型对评估单基因病及产前咨询和评估巨头畸形胎儿至关重要。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the diagnostic utility of exome sequencing (ES) in macrocephalic fetuses. METHODS: Fetuses with macrocephaly (head circumference (HC) ≥ +2 SD) and negative chromosomal microarray results were included, who had available trio-ES data. Molecular diagnoses were systematically analyzed. Subgroup analyses were performed on the ES diagnostic yield based on gestational age, HC Z-scores, associated anomalies, and growth parameters. RESULTS: Molecular diagnoses were established in 34 out of 87 macrocephalic fetuses (39.1%) through trio-ES. These diagnoses revealed that the variants predominantly affect key signaling pathways, including mTOR, RASopathies and Sotos syndrome. The detection rate was significantly higher in non-isolated compared to isolated macrocephaly cases (65.0%, 26/40 vs. 17.0%, 8/47; p < 0.001). The most frequent anomalies associated with genetic diagnoses included micromelia (100.0%, 14/14), megalencephaly (100.0%, 2/2), and ventriculomegaly (60.0%, 6/10). Subgroup analysis identified higher diagnostic yields in fetuses diagnosed before 32 gestational weeks, with HC Z-scores ≥ +3 SD, micromelia, and absence of large-for-gestational-age (LGA). CONCLUSIONS: Exome sequencing significantly enhances the detection of monogenic disorders in macrocephalic fetuses compared with CMA, irrespective of isolated or non-isolated cases. These clinical features and phenotypes are essential for assessing monogenic disorders and for prenatal counseling and evaluations of macrocephalic fetuses.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Zhou H, Fu F, Huang R, et al. Prenatal Exome Sequencing for Fetal Macrocephaly: A Large Prospective Observational Cohort Study. Prenat Diagn. 2025. PMID: 40404351. doi:10.1002/pd.6818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。